1. Home
  2. LEXX vs UTSI Comparison

LEXX vs UTSI Comparison

Compare LEXX & UTSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEXX
  • UTSI
  • Stock Information
  • Founded
  • LEXX 2004
  • UTSI 1991
  • Country
  • LEXX Canada
  • UTSI China
  • Employees
  • LEXX N/A
  • UTSI N/A
  • Industry
  • LEXX Biotechnology: Pharmaceutical Preparations
  • UTSI Telecommunications Equipment
  • Sector
  • LEXX Health Care
  • UTSI Telecommunications
  • Exchange
  • LEXX Nasdaq
  • UTSI Nasdaq
  • Market Cap
  • LEXX 22.7M
  • UTSI 22.6M
  • IPO Year
  • LEXX N/A
  • UTSI 2000
  • Fundamental
  • Price
  • LEXX $1.13
  • UTSI $2.52
  • Analyst Decision
  • LEXX Strong Buy
  • UTSI
  • Analyst Count
  • LEXX 1
  • UTSI 0
  • Target Price
  • LEXX $4.00
  • UTSI N/A
  • AVG Volume (30 Days)
  • LEXX 212.4K
  • UTSI 4.1K
  • Earning Date
  • LEXX 01-09-2026
  • UTSI 08-29-2025
  • Dividend Yield
  • LEXX N/A
  • UTSI N/A
  • EPS Growth
  • LEXX N/A
  • UTSI N/A
  • EPS
  • LEXX N/A
  • UTSI N/A
  • Revenue
  • LEXX $615,923.00
  • UTSI $9,793,000.00
  • Revenue This Year
  • LEXX $46.98
  • UTSI N/A
  • Revenue Next Year
  • LEXX $17.26
  • UTSI N/A
  • P/E Ratio
  • LEXX N/A
  • UTSI N/A
  • Revenue Growth
  • LEXX 49.85
  • UTSI N/A
  • 52 Week Low
  • LEXX $0.77
  • UTSI $1.84
  • 52 Week High
  • LEXX $2.85
  • UTSI $3.00
  • Technical
  • Relative Strength Index (RSI)
  • LEXX 57.12
  • UTSI 50.48
  • Support Level
  • LEXX $1.00
  • UTSI $2.40
  • Resistance Level
  • LEXX $1.19
  • UTSI $2.59
  • Average True Range (ATR)
  • LEXX 0.08
  • UTSI 0.05
  • MACD
  • LEXX -0.00
  • UTSI 0.00
  • Stochastic Oscillator
  • LEXX 66.25
  • UTSI 58.33

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

About UTSI UTStarcom Holdings Corp.

UTStarcom Holdings Corp is providing telecommunication network products, solutions and services. It focus on delivering carrier-class packet optical, network synchronization and broadband access (both wireless and fixed line) products and solutions, coupled with Software Defined Networking (SDN) platform, optimized for mobile backhaul, metro aggregation, broadband access and value added services. The business activity of the firm is operated through the Equipment and Service segment. The Equipment segment is focused on equipment sales, including network infrastructure and application products, and the Service segment is engaged in providing services and support of equipment products and also the new operational support. Key revenue is generated from Equipment segment.

Share on Social Networks: